Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Stankoff

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Neurology|September 4, 2025
Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated DiseaseRosa Cortese, Francesco Sforazzini, Giordano Gentile, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?Claire Rouzaud, Patrick Hautecoeur, Cécile Donze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
JAMA Neurology|June 27, 2020
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisCéline Louapre, Nicolas Collongues, Bruno Stankoff, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.
Neurology|September 4, 2025
Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated DiseaseRosa Cortese, Francesco Sforazzini, Giordano Gentile, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?Claire Rouzaud, Patrick Hautecoeur, Cécile Donze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
JAMA Neurology|June 27, 2020
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisCéline Louapre, Nicolas Collongues, Bruno Stankoff, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Pageof 16